LINC02930: A protein involved in cell adhesion and multiple diseases

Target Name: LINC02930

NCBI ID: G105378516

LINC02930

Other Name(s): LOC105378516 | Uncharacterized LOC105378516 | long intergenic non-protein coding RNA 2930

LINC02930: A protein involved in cell adhesion and multiple diseases

LINC02930 (LOC105378516) is a protein that is expressed in various tissues of the human body, including the brain, heart, and liver. It is a key regulator of cell adhesion and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its role in cell adhesion, LINC02930 has also been shown to play a number of other important functions in the body. For example, it is involved in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. This is important for maintaining the health and function of the brain and is a potential target for drugs that are intended to treat brain diseases.

In addition to its role in the blood-brain barrier, LINC02930 is also involved in the regulation of cell signaling pathways that are important for many different cellular processes, including cell growth, differentiation, and survival. This is important for the development and progression of many diseases, including cancer.

One of the ways that LINC02930 is involved in cell signaling pathways is through its role as a negative regulator of the NF-kappa pathway. NF-kappa is a protein that is involved in the regulation of cell growth and differentiation, and it is often activated in response to changes in the environment, such as the presence of growth factors. LINC02930 is shown to play a negative role in the regulation of NF-kappa, which means that it works to inhibit the activity of NF-kappa and to prevent it from causing unnecessary cell growth and differentiation.

Another way that LINC02930 is involved in cell signaling pathways is through its role as a negative regulator of the PDGF signaling pathway. PDGF is a protein that is involved in the regulation of cell growth and differentiation, and it is often activated in response to changes in the environment, such as the presence of its own signal. LINC02930 is shown to play a negative role in the regulation of PDGF, which means that it works to inhibit the activity of PDGF and to prevent it from causing unnecessary cell growth and differentiation.

In addition to its role in the regulation of cell signaling pathways, LINC02930 is also involved in the regulation of cellular processes that are important for many different cellular functions, including cell survival and stress resistance. This is important for the development and progression of many diseases, including cancer.

Given its involvement in a number of important cellular processes, LINC02930 is a potential drug target for a variety of diseases. For example, it is possible that LINC02930 could be a good candidate for treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, which are characterized by the progressive loss of brain cells. Additionally, LINC02930 is also shown to be involved in the regulation of the blood-brain barrier, which means that it could be a good candidate for treatment of brain cancers, such as glioblastoma.

In conclusion, LINC02930 is a protein that is expressed in various tissues of the human body and is involved in a number of important cellular processes. It is a potential drug target for a variety of diseases, including neurodegenerative diseases and brain cancers. Further research is needed to fully understand the role of LINC02930 in the regulation of cellular processes and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2930

The "LINC02930 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02930 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets